Patient‐reported outcomes: active surveillance vs radical therapies in low‐risk prostate cancer
Active surveillance is underutilised in the observed cohort. Prospective PCO data demonstrates that AS preserves urinary continence and sexual function compared to active treatment, supporting its role as the first-line strategy for suitable candidates. Despite advancements including NS techniques, RP, and to a lesser extent RT, remain associated with substantial functional impairment even in younger men.
Authors
- Inga Peters (ORCID: https://orcid.org/0000-0001-7549-9342)
- Mario W. Kramer (ORCID: https://orcid.org/0000-0002-0288-5872)
- Philipp Huber
- Jens Tonhauser
- Jens Peter Sommer
- Sameh Hijazi (ORCID: https://orcid.org/0000-0002-3044-2075)
- Lukas Prause (ORCID: https://orcid.org/0000-0002-1563-3543)
- Sebastian Lenart (ORCID: https://orcid.org/0000-0002-7609-1207)
- Mohamad Hatem Albarghouth (ORCID: https://orcid.org/0000-0002-0939-8858)
- G Feick
- C Kowalski
- Lukas Manka (ORCID: https://orcid.org/0000-0002-1775-2220)
- V. Zimmermanns
- Ferdinand Luger (ORCID: https://orcid.org/0000-0002-7806-4819)
- Boris Hadaschik (ORCID: https://orcid.org/0000-0002-1052-2692)
- Bülent Polat (ORCID: https://orcid.org/0000-0002-1790-6808)
- Nina N. Harke (ORCID: https://orcid.org/0000-0002-6154-7101)
- P. Miglierini
- Jan Fichtner (ORCID: https://orcid.org/0000-0001-7675-400X)
- Thomas Hermanns
- Rein Jüri Palisaar
- Martin Burchardt
- Nora Tabea Sibert
- Andreas Neisius
- Guenther Carl
- Osama Mahmoud
- Thomas Knoll
- Matthias Reichert
- Julia Schittko
- Alexander Winter
- Mulham Al‐Nader
- Marcus Horstmann
- Jesco Pfitzenmaier
- Marko Brock
- Andreas Blana
- Eva‐Maria Kunzmann
- Daniel Porres
- Kinan Almansur
- Anna Calderaro
- Matthias Saar
- Claudia Kesch
- Lukas Hefermehl
- Kristina Wiens
Institutions
- Trier University of Applied Sciences (DE)
- University of Fribourg (CH)
- Universitätsmedizin Greifswald (DE)
- University Hospitals of the Ruhr-University of Bochum (DE)
- Medizinische Hochschule Hannover (DE)
- Universitätsklinik Marien Hospital Herne (DE)
- Düsseldorf University Hospital (DE)
- Hirslanden Klinik Im Park (CH)
- Rems-Murr-Klinikum (DE)
- Die Johanniter (DE)
- Alb Fils Kliniken (DE)
- German Cancer Society (DE)
- Fribourg Development Agency (CH)
- Evangelisches Krankenhaus Bielefeld (DE)
- Klinikum Oldenburg (DE)
- Evangelisches Krankenhaus Oberhausen (DE)
- Bundesverband Glaukom-Selbsthilfe (DE)
- Klinikum Braunschweig (DE)
- Deutsche Schmerzgesellschaft (DE)
- Nephrologisches Zentrum Goettingen (DE)
- Klinikum Lüneburg (DE)
- Essen University Hospital (DE)
- Kantonsspital Baden (CH)
- Hospital of the Brothers of St. John of God (AT)
- Universitätsklinikum Würzburg (DE)
- Hegau-Bodensee-Klinikum Singen (DE)
- Brüderkrankenhaus St. Josef Paderborn (DE)
- Krankenhaus Nordwest (DE)
- Hirslanden Klinik St. Anna (CH)
- University Hospital Magdeburg (DE)
- Stadtarchiv Ibbenbüren (DE)
- Klinikum Sindelfingen-Böblingen (DE)
- Miele (Germany) (DE)
- AGO Austria (AT)
- Theologische Fakultät Fulda (DE)
- Alfried Krupp Hospital (DE)
- Klinikum Leverkusen (DE)
- University Hospital Ulm (DE)
- Siloah St. Trudpert Klinikum (DE)
- Klinikum Fulda (DE)
- Kantonsspital Aarau (CH)
- Heinrich Heine University Düsseldorf (DE)
- Friedrich Schiller University Jena (DE)
- RWTH Aachen University (DE)
- Universität Trier (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1111/bju.70167
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- AstraZeneca
- Bayer
- Advanced Accelerator Applications
- Deutsche Forschungsgemeinschaft
- European Association of Urology
- Astellas Pharma
- Deutsche Krebshilfe
- Janssen Pharmaceuticals